- Home
- DRCT vs NXL Comparison
DRCT vs NXL Comparison
Compare DRCT & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- NXL
- Stock Information
- Founded
- DRCT 2018
- NXL 2010
- Country
- DRCT United States
- NXL United States
- Employees
- DRCT N/A
- NXL N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- NXL Medical Specialities
- Sector
- DRCT Technology
- NXL Health Care
- Exchange
- DRCT Nasdaq
- NXL Nasdaq
- Market Cap
- DRCT 38.7M
- NXL 31.1M
- IPO Year
- DRCT 2022
- NXL 2022
- Fundamental
- Price
- DRCT $0.77
- NXL $2.25
- Analyst Decision
- DRCT Strong Buy
- NXL Strong Buy
- Analyst Count
- DRCT 3
- NXL 1
- Target Price
- DRCT $21.00
- NXL $5.00
- AVG Volume (30 Days)
- DRCT 107.0K
- NXL 143.7K
- Earning Date
- DRCT 04-01-2025
- NXL 03-14-2025
- Dividend Yield
- DRCT N/A
- NXL N/A
- EPS Growth
- DRCT N/A
- NXL N/A
- EPS
- DRCT N/A
- NXL N/A
- Revenue
- DRCT $94,216,000.00
- NXL $168,721.00
- Revenue This Year
- DRCT N/A
- NXL $175.37
- Revenue Next Year
- DRCT $37.23
- NXL $334.78
- P/E Ratio
- DRCT N/A
- NXL N/A
- Revenue Growth
- DRCT N/A
- NXL 52.35
- 52 Week Low
- DRCT $0.51
- NXL $0.50
- 52 Week High
- DRCT $29.75
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- DRCT 37.13
- NXL 45.51
- Support Level
- DRCT $0.74
- NXL $2.28
- Resistance Level
- DRCT $0.85
- NXL $2.57
- Average True Range (ATR)
- DRCT 0.09
- NXL 0.23
- MACD
- DRCT 0.01
- NXL 0.04
- Stochastic Oscillator
- DRCT 40.47
- NXL 65.08
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.